CAR-T cell therapy has revolutionized cancer treatment, but its efficacy against solid tumors remains limited due to challenges like poor CAR-T cell in-vivo survival. Tikva’s engineered SB9 EBVST platform will not only address a major resistance mechanism axis but also opens doors to more effective CAR T cell therapies for solid tumors.
SINGAPORE – 8 Jul 2024 – Tikva Allocell Scientists published scientific article in Cell Molecular Therapy on Novel OX40 and 4-1BB Derived Spacers Enhance CD30 CAR Activity and Safety in CD30 Positive Lymphoma Models. The chimeric antigen receptor is made up of several domain, all of which have important roles to play in determining the …
Research Article – Overexpression of an Engineered SerpinB9 Enhances Allogeneic T-Cell Persistence and Efficacy
SINGAPORE – 28 May 2024 – Tikva Allocell scientists publish scientific article in Cancer Research Communications on a promising off-the-shelf CAR T cell therapy targeting B7-H3 positive solid tumors. Despite the significant advances of CAR T cell therapy in blood cancer treatment, its success in solid tumors remains limited. In this paper, we show that with …